EUTECNIQAtlas

Every page of EUTECNIQ on one mapArrow keys move through results · Enter opens · Esc closes

Supplements A–Z Botanical Sources: 11

Holy basil Ocimum tenuiflorum L.

Also called: tulsi, sacred basil, Rama tulsi, Ocimum sanctum (synonym)

Holy basil (tulsi) is a basil species highly revered in Ayurvedic and Siddha medicine. Supplements and teas use the dried leaf or leaf extracts; green and purple types are traded.

Category
Botanical
Part used
Leaf (dried leaf or leaf extracts)
Strongest evidence
C Limited
Native range
Native from tropical and subtropical Asia to the western Pacific (POWO: "Trop. & Subtrop. Asia to W. Pacific")
Reviewed
2026-10-29

Class 1 Well studied in people. A 2017 systematic review (Evid Based Complement Alternat Med) of tulsi as a single herb found 24 human studies (not pooled), almost all from India. Its text classes 13 as randomized (6 placebo-controlled); its tables label 11 distinct trials randomized and placebo- or otherwise controlled (Mondal 2011/2012 counted once). [7]

Fact-checked 2026-10-29 · How this guide is made

Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.

Evidence

What research has studied

Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.

6 topics studied3 body areas · strongest grade C

A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials

From the table below Each topic in the table is placed on the part of the body it names, colored by its strongest grade. Tap an area, or open a line in the list, to see its topics. The map shows what was studied, not what Holy basil does: a C or X area is not evidence of benefit. All 1,071 findings on one body map.
Topics studied for Holy basil, evidence grade and finding
Topic studiedGradeWhat the evidence shows
Perceived stress in adults (8-week trial)CIn an industry-funded RCT of 100 stressed adults (125 mg twice daily), Perceived Stress Scale scores and hair cortisol fell more than with placebo; sleep-scale scores also improved. [3]
General stress symptoms (6-week trial)CIn a placebo-controlled trial of 150 adults (1,200 mg actives/day), total stress-symptom scores fell significantly more than with placebo; no adverse events were reported. [4]
Sleep in stressed adultsCIn an 8-week placebo-controlled RCT of 100 stressed adults, Athens Insomnia Scale scores improved more than with placebo; the authors said objective sleep measures are needed to confirm this. [3]
Blood glucose in type 2 diabetesCA single-blind, placebo-controlled crossover trial (1996) reported fasting glucose 21.0 mg/dl and post-meal glucose 15.8 mg/dl lower with holy basil leaves than placebo leaves. [5]
Cognitive performance in healthy adultsCOne 30-day placebo-controlled study (300 mg/day leaf extract) reported faster reaction times and fewer errors on Sternberg and Stroop tests. [6]
Metabolic, cardiovascular, immune and neurocognitive outcomesCA 2017 systematic review found 24 human studies, all reporting favorable outcomes and none reporting significant adverse events; authors called for work on dose, dose form and who benefits. [7]

Main constituents: Eugenol, rosmarinic acid, apigenin, myrtenal, luteolin, beta-sitosterol and carnosic acid; flavonoids orientin and vicenin [1]; Purple tulsi contains more methyl eugenol than green tulsi [2]

Amounts

Amounts studied and limits

Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.

  • 125 mg of a standardized extract twice daily for 8 weeks (trial). [3]
  • 1,200 mg of actives per day for 6 weeks (trial). [4]
  • 300 mg/day of ethanolic leaf extract for 30 days (trial). [6]
  • Stated in Health Canada's monograph (Canada, February 27, 2026), adults: dry or ethanolic preparations 2-3 g dried leaf per day (Ayurveda or adaptogen uses; not to exceed 3 g as an antioxidant); aqueous preparations 7-28 g (Ayurveda) or 4.2-28 g (adaptogen) dried leaf per day, not to exceed 28 g as an antioxidant. [8]

No official upper intake level has been set.

Safety

Safety and side effects

  • Liver (NIH LiverTox)
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Pregnancy and breastfeeding
    Health Canada monograph: do not use if pregnant; ask a practitioner before use if breastfeeding.

    1 statement in the profile.

    Details and sources
  • Interactions with medicines
    1 listed

    Heart or blood pressure medication

    Details and sources
  • Cancer evaluations (IARC, NTP)
    1 found

    Each names the exact material tested, which may differ from a supplement.

    Details and sources
  • FDA new dietary ingredient notifications
    None on FDA's list

    FDA does not approve dietary supplements. Each entry is one party's filing.

    Details and sources
  • Dose in official monographs
    Stated

    Stated in Health Canada's monograph (Canada, February 27, 2026), adults: dry or ethanolic preparations 2-3 g dried leaf per day (Ayurveda or …

    Details and sources
  • Health Canada: do not use if pregnant; ask a practitioner before use if breastfeeding, if you have a heart condition or diabetes, or take heart or blood pressure medication. [8]
  • The 8-week trial reported good tolerability with no major adverse effects. [3]
  • No significant adverse events were reported in the 24 human studies reviewed in 2017. [7]
Interactions

Interactions

Known interactions of Holy basil
WithWhat happens
Heart or blood pressure medicationHealth Canada requires a caution to ask a practitioner before use when taking these medicines. [8]

Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.

Quality

Identity, quality and standardization

  • A 2024 study of 30 market tulsi powders found 80% were purple tulsi (richer in methyl eugenol), about 10% mixed, and two samples were a different species, Ocimum gratissimum. [2]
Regulation

Regulatory status

  • Canada: Health Canada monograph (February 27, 2026) for traditional Ayurvedic and herbal (adaptogen) uses of the dried leaf and as a source of antioxidants. [8]
  • US: FDA states that, by law, it does not approve dietary supplements or their labeling; under DSHEA it has no authority to approve them before they are marketed, and firms are responsible for their products' safety and labeling. [9]
Profile

Safety, quality and supply profile

Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.

Compounds responsible

Compounds the sources name as the main or characteristic actives.

  • Eugenol Phenylpropanoid (phenol) [P1]
  • Rosmarinic acid Phenolic acids [P1]
  • Apigenin, luteolin, orientin, vicenin Flavonoids [P1]

US status

What FDA's published records show. FDA does not approve dietary supplements.

  • No NDI notification naming holy basil (Ocimum tenuiflorum / O. sanctum, tulsi) was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-29). FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [P2]

Cancer evaluations (IARC and NTP)

Evaluations name the exact material tested, which may differ from a supplement.

  • No IARC or NTP carcinogenicity evaluation of holy basil (Ocimum tenuiflorum) was found (IARC Monographs list of classifications and NTP technical reports checked 2026-10-29). [P3]
  • Methyleugenol (reported at higher levels in purple tulsi) is classified by IARC in Group 2A (Volumes 101 and 134; evaluated 2023); this classification concerns the pure compound, not holy basil. [P3]

Liver (NIH LiverTox)

  • No published information found in the sources checked.

Interactions with medicines

  • Heart or blood pressure medication: Health Canada requires a caution to ask a practitioner before use when taking these medicines. [P4]

Alcohol

  • No published information found in the sources checked.

Interactions with other herbs and supplements

  • No published information found in the sources checked.

Adulteration and substitution

  • A 2024 study of 30 market tulsi powders found 80% were purple tulsi (richer in methyl eugenol), about 10% mixed, and two samples were a different species, Ocimum gratissimum. [P5]

What a certificate of analysis should cover

Tests a quality specification for this material would include, with the reason for each.

  • Identity test or examination of each dietary-ingredient component before use — 21 CFR 111.75(a)(1)(i) requires at least one appropriate identity test or examination unless FDA grants an exemption petition under 111.75(a)(1)(ii). [P6]
  • Allele-specific PCR to distinguish green and purple tulsi and detect other Ocimum species — Purple tulsi contains more methyl eugenol, and Ocimum gratissimum was found in market samples. [P5]

Supply and conservation

  • No published information found in the sources checked.

Absorption in people

  • No published information found in the sources checked.

Formulations studied to change absorption

Human data only.

  • No published information found in the sources checked.

Dose in official monographs

As the monograph states it, for its jurisdiction; not personal advice.

  • Stated in Health Canada's monograph (Canada, February 27, 2026), adults: dry or ethanolic preparations 2-3 g dried leaf per day (Ayurveda or adaptogen uses; not to exceed 3 g as an antioxidant); aqueous preparations 7-28 g (Ayurveda) or 4.2-28 g (adaptogen) dried leaf per day, not to exceed 28 g as an antioxidant. [P4]

Pregnancy and breastfeeding

  • Health Canada monograph: do not use if pregnant; ask a practitioner before use if breastfeeding. [P4]

Sources for this profile

  1. Baliga MS, et al. Ocimum sanctum L (holy basil or tulsi) and its phytochemicals in the prevention and treatment of cancer. Nutr Cancer 2013;65 Suppl 1:26-35 (PMID 23682780), 2013. pubmed.ncbi.nlm.nih.gov
  2. FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
  3. IARC Monographs on the Identification of Carcinogenic Hazards to Humans. List of Classifications (checked 2026-10-29), 2026-10-29. monographs.iarc.who.int
  4. Health Canada, Natural and Non-prescription Health Products Directorate. Monograph: Holy Basil - Ocimum tenuiflorum - Leaf (dated February 27, 2026), 2026-02-27. webprod.hc-sc.gc.ca
  5. Balaji R, Parani M. Development of an allele-specific PCR (AS-PCR) method for identifying high-methyl eugenol-containing purple tulsi (Ocimum tenuiflorum L.) in market samples. Mol Biol Rep 2024;51(1):439 (PMID 38520476), 2024-03-23. pubmed.ncbi.nlm.nih.gov
  6. eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (current text, checked 2026-10-29), 2026-10-29. ecfr.gov
Sources

Sources

  1. Baliga MS, et al. Ocimum sanctum L (holy basil or tulsi) and its phytochemicals in the prevention and treatment of cancer. Nutr Cancer 2013;65 Suppl 1:26-35 (PMID 23682780), 2013. pubmed.ncbi.nlm.nih.gov
  2. Balaji R, Parani M. Development of an allele-specific PCR (AS-PCR) method for identifying high-methyl eugenol-containing purple tulsi (Ocimum tenuiflorum L.) in market samples. Mol Biol Rep 2024;51(1):439 (PMID 38520476), 2024-03-23. pubmed.ncbi.nlm.nih.gov
  3. Lopresti AL, et al. A randomized, double-blind, placebo-controlled trial investigating the effects of an Ocimum tenuiflorum (holy basil) extract (Holixer) on stress, mood, and sleep in adults experiencing stress. Front Nutr 2022;9:965130 (PMID 36185698), 2022-09-02. pubmed.ncbi.nlm.nih.gov
  4. Saxena RC, et al. Efficacy of an extract of Ocimum tenuiflorum (OciBest) in the management of general stress: a double-blind, placebo-controlled study. Evid Based Complement Alternat Med 2012;2012:894509 (PMID 21977056), 2012. pubmed.ncbi.nlm.nih.gov
  5. Agrawal P, Rai V, Singh RB. Randomized placebo-controlled, single blind trial of holy basil leaves in patients with noninsulin-dependent diabetes mellitus. Int J Clin Pharmacol Ther 1996;34(9):406-409 (PMID 8880292), 1996-09. pubmed.ncbi.nlm.nih.gov
  6. Sampath S, et al. Holy basil (Ocimum sanctum Linn.) leaf extract enhances specific cognitive parameters in healthy adult volunteers: a placebo controlled study. Indian J Physiol Pharmacol 2015;59(1):69-77 (PMID 26571987), 2015. pubmed.ncbi.nlm.nih.gov
  7. Jamshidi N, Cohen MM. The clinical efficacy and safety of tulsi in humans: a systematic review of the literature. Evid Based Complement Alternat Med 2017;2017:9217567 (PMID 28400848), 2017-03-16. pubmed.ncbi.nlm.nih.gov
  8. Health Canada, Natural and Non-prescription Health Products Directorate. Monograph: Holy Basil - Ocimum tenuiflorum - Leaf (dated February 27, 2026), 2026-02-27. webprod.hc-sc.gc.ca
  9. U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
  10. Plants of the World Online (POWO), Royal Botanic Gardens, Kew; WCVP data. Ocimum tenuiflorum L. (accessed 2026-10-29), 2026-10-29. powo.science.kew.org
  11. WCVP via GBIF species API: Ocimum sanctum L., synonym of Ocimum tenuiflorum L. (retrieved 2026-10-29), 2026-10-29. api.gbif.org
A
Consistent results from several randomized trials or a systematic review of them
B
Some positive randomized trials, but small, short, few or inconsistent
C
Limited human evidence: single small trials, observational data or mixed results
D
Laboratory or animal evidence only; not shown in people
X
Well-designed human trials found no meaningful effect

More in botanical: Aloe vera · American ginseng · Amla · Andrographis · Arjuna · Arnica · Aronia (black chokeberry) · Asafoetida · All entries A–Z · How to judge a supplement

Health information notice

These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.

Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to check what you take?

Free tools built on published reference values, each with its sources and its limits. Your lists stay in your browser.